Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks

ClinicalTrials.gov ID: NCT00147498

Public ClinicalTrials.gov record NCT00147498. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 11:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Compare 3 Dose Levels Of CP-690,550 Versus Placebo, Administered Orally Twice Daily (BID) For 6 Weeks, In The Treatment Of The Signs And Symptoms Of Subjects With Active Rheumatoid Arthritis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The study's objective is to compare the efficacy of 3 dose levels of oral CP-690,550 monotherapy (5 mg, 15 mg, and 30 mg twice daily \[BID\]) versus placebo administered over 6 weeks for the treatment of the signs and symptoms of subjects with active rheumatoid arthritis (RA).

Study identification

NCT ID
NCT00147498
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Pfizer
Industry
Enrollment
264 participants

Conditions and interventions

Interventions

Drug · Other

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 2005 (Type not available)
Primary completion
Jun 2006 (Actual)
Completion
Jun 2006 (Actual)
Last update posted
Jan 30, 2013

2005 – 2006

United States locations

U.S. sites
24
U.S. states
12
U.S. cities
22
Facility City State ZIP Site status
Pfizer Investigational Site Upland California 91786 —
Pfizer Investigational Site Clearwater Florida 33765 —
Pfizer Investigational Site Miami Florida 33173 —
Pfizer Investigational Site New Port Richey Florida 34652 —
Pfizer Investigational Site Ocala Florida 34474-7455 —
Pfizer Investigational Site Orlando Florida 32804 —
Pfizer Investigational Site Port Richey Florida 34668 —
Pfizer Investigational Site Tampa Florida 33614 —
Pfizer Investigational Site Dubuque Iowa 52001-7313 —
Pfizer Investigational Site Dubuque Iowa 52002 —
Pfizer Investigational Site Concord New Hampshire 03301 —
Pfizer Investigational Site Plainview New York 11803 —
Pfizer Investigational Site Charlotte North Carolina 28210 —
Pfizer Investigational Site Hickory North Carolina 28601 —
Pfizer Investigational Site Hickory North Carolina 28602 —
Pfizer Investigational Site Dayton Ohio 45402 —
Pfizer Investigational Site Ducansville Pennsylvania 16635 —
Pfizer Investigational Site Johnstown Pennsylvania 15904 —
Pfizer Investigational Site Charleston South Carolina 29406 —
Pfizer Investigational Site Columbia South Carolina 29204 —
Pfizer Investigational Site Nashville Tennessee 37203 —
Pfizer Investigational Site Dallas Texas 75231-4496 —
Pfizer Investigational Site Everett Washington 98201 —
Pfizer Investigational Site Tacoma Washington 98405 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 36 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00147498, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 30, 2013 · Synced Oct 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00147498 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →